CTSB and acute lymphoblastic leukemia: In all conditions, CTSB KO cells remained resistant to ASNase treatment, as demonstrated by the retention of ALL cell viability and IC50, implicating additional key factors, such as tumor environment and immune system, in the inherent or induced ASNase resistance and, ultimately, inefficient cancer treatment.